Last reviewed · How we verify
AMG 509
At a glance
| Generic name | AMG 509 |
|---|---|
| Also known as | xaluritamig |
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer (PHASE1)
- Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) (PHASE1)
- Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer (PHASE1)
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (PHASE3)
- Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer (PHASE1)
- Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer (PHASE1)
- Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |